


# Retinitis Pigmentosa Market In 2029

*The Business Research Company's Retinitis Pigmentosa Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED KINGDOM, December 19, 2025 /EINPresswire.com/ -- [Retinitis Pigmentosa Market](#) to Surpass \$17 billion in 2029. Within the broader Healthcare Services industry, which is expected to be \$10,759 billion by 2029, the Retinitis Pigmentosa market is estimated to account for nearly 2% of the total market value.



Which Will Be the Biggest Region in [the Retinitis Pigmentosa Market in 2029](#)



The Business Research Company's Retinitis Pigmentosa Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034"

*The Business Research Company*

Asia-Pacific will be the largest region in the retinitis pigmentosa market in 2029, valued at \$5,572 million. The market is expected to grow from \$3,287 million in 2024 at a compound annual growth rate (CAGR) of 11%. The rapid growth can be attributed to the rising prevalence of inherited retinal diseases, rising advancements in gene and stem cell therapy, rising government funding for rare disease research, rising adoption of advanced diagnostic technologies, rising awareness and early screening programs and rising geriatric population.

Which Will Be The Largest Country In The Global Retinitis Pigmentosa Market In 2029?

The USA will be the largest country in the retinitis pigmentosa market in 2029, valued at \$4,859 million. The market is expected to grow from \$3,671 million in 2024 at a compound annual growth rate (CAGR) of 6%. The strong growth can be attributed to the rising adoption of gene and stem cell therapies, expanding government funding for rare disease research, increasing availability of advanced diagnostic technologies and rising aging population.

Request a free sample of the Retinitis Pigmentosa Market report:


[https://www.thebusinessresearchcompany.com/sample\\_request?id=16528&type=smp](https://www.thebusinessresearchcompany.com/sample_request?id=16528&type=smp)

## What will be Largest Segment in the Retinitis Pigmentosa Market in 2029?

The retinitis pigmentosa market is segmented by type into autosomal recessive, autosomal dominant and X-linked. The autosomal recessive market will be [the largest segment of the retinitis pigmentosa market](#) segmented by type, accounting for 49% or \$8,308 million of the total in 2029. The autosomal recessive market will be supported by increasing prevalence of inherited retinal disorders, growing awareness and genetic counseling programs, advancements in gene therapy targeting recessive mutations, rising research funding for rare genetic diseases, expanding newborn screening initiatives and improved diagnostic capabilities for early detection.

The retinitis pigmentosa market is segmented by treatment into vitamin A, docosahexaenoic acid (DHA), calcium channel blockers, gene therapy, retinal eye prosthetics and other treatments. The vitamin A market will be the largest segment of the retinitis pigmentosa market segmented by treatment, accounting for 33% or \$5,546 million of the total in 2029. The vitamin A market will be supported by established benefits in slowing disease progression, increasing physician recommendations for supplementation, growing consumer awareness about eye health, rising demand for dietary interventions in retinal diseases, expanding availability of high-quality vitamin A formulations and inclusion in clinical treatment guidelines.

The retinitis pigmentosa market is segmented by diagnosis into electroretinogram, visual field testing, genetic testing and other diagnostic methods. The electroretinogram market will be the largest segment of the retinitis pigmentosa market segmented by diagnosis, accounting for 42% or \$7,142 million of the total in 2029. The electroretinogram market will be supported by effectiveness in detecting early functional changes in the retina, increasing availability of advanced ERG testing devices, growing adoption in ophthalmology clinics and research centers, rising awareness about early diagnosis benefits, expanding insurance coverage for diagnostic tests and improvements in portable ERG technology for home-based monitoring



The retinitis pigmentosa market is segmented by distribution channel into hospital pharmacy, retail pharmacy, online pharmacy and other distribution channels. The hospital pharmacy market will be the largest segment of the retinitis pigmentosa market segmented by distribution channel, accounting for 44% or \$7,424 million of the total in 2029. The hospital pharmacy market will be supported by increasing hospital admissions for advanced eye care, growing availability of specialized ophthalmic medications, rising integration of electronic health records for prescription tracking, expanding access to gene therapy drugs in hospital settings, increasing collaboration between hospitals and pharmaceutical companies and government initiatives to improve hospital pharmacy infrastructure.

The retinitis pigmentosa market is segmented by end-users into hospitals, specialty clinics, homecare and other end-users. The specialty clinics market will be the largest segment of the retinitis pigmentosa market segmented by end-users, accounting for 39% or \$6,577 million of the total in 2029. The specialty clinics market will be supported by growing preference for specialized eye care centers, increasing number of clinics offering genetic counseling, rising demand for personalized treatment plans, expanding access to clinical trials, advancements in diagnostic technology for early detection and improved patient education programs for disease management.

What is the expected CAGR for the Retinitis Pigmentosa Market leading up to 2029?

The expected CAGR for the retinitis pigmentosa market leading up to 2029 is 9%

What Will Be The Growth Driving Factors In The Global Retinitis Pigmentosa Market In The Forecast Period?

The rapid growth of the global retinitis pigmentosa market leading up to 2029 will be driven by the following key factors that are expected to reshape therapeutic innovation, precision medicine development, and patient care strategies across the ophthalmology sector worldwide.

**Rising Investments In Research And Development** - The increasing emphasis on investments in research and development will become a key driver of growth in the retinitis pigmentosa market by 2029. Increased funding from government agencies, pharmaceutical companies, and biotech firms is accelerating the development of innovative therapies, including gene therapy, stem cell treatments, and optogenetics. Advancements in clinical research are expanding the pipeline of potential treatments, improving patient outcomes, and increasing market opportunities. Growing collaborations between research institutions and industry players are also enhancing drug discovery and speeding up regulatory approvals. As a result, the growing deployment of investments in research and development is anticipated to contributing to a 2.0% annual growth in the market.

**Rising Strategic Collaborations and Partnerships** - The growing focus on collaborations and partnerships will emerge as a major factor driving the expansion of the retinitis pigmentosa market by 2029. Pharmaceutical companies, biotech firms, and research institutions are increasingly forming alliances to accelerate the development of gene therapies, stem cell

treatments, and innovative drug candidates. These collaborations facilitate knowledge sharing, improve access to advanced technologies, and enhance funding for clinical trials. Consequently, the accelerating adoption of collaborations and partnerships capabilities is projected to contributing to a 1.5% annual growth in the market.

**Higher Healthcare Expenditure** - The expanding integration of healthcare expenditure processes will serve as a key growth catalyst for the retinitis pigmentosa market by 2029. Increased government and private sector spending on healthcare is improving access to advanced diagnostic tools, genetic testing, and innovative treatments such as gene therapy and stem cell-based approaches. Rising investment in ophthalmic research and specialized care facilities is also accelerating drug development and clinical trials. Therefore, this growing integration of healthcare expenditure operations is projected to supporting to a 1.0% annual growth in the market.

**Growing Geriatric Population** - The increasing emphasis on geriatric population will become a significant driver contributing to the growth of the retinitis pigmentosa market by 2029. As life expectancy increases, the number of aging individuals at risk of retinal degenerative diseases rises, leading to greater demand for effective treatments. Older adults are more likely to experience vision-related disorders, increasing the need for advanced diagnostic tools, gene therapies, and regenerative medicine. Consequently, the rising adoption of geriatric population strategies is projected to contributing to a 0.5% annual growth in the market.

Access the detailed Retinitis Pigmentosa report here:

<https://www.thebusinessresearchcompany.com/report/retinitis-pigmentosa-global-market-report>

**What Are The Key Growth Opportunities In The Retinitis Pigmentosa Market in 2029?**

The most significant growth opportunities are anticipated in the autosomal recessive retinitis pigmentosa market, the retinitis pigmentosa specialty clinics market, the online pharmacy for retinitis pigmentosa market, the electroretinogram retinitis pigmentosa market, and the retinitis pigmentosa and vitamin A therapeutics market. Collectively, these segments are projected to contribute over \$11 billion in market value by 2029, driven by advancements in gene-based therapies, early diagnostic innovations, and the rising prevalence of inherited retinal disorders. This surge reflects the accelerating focus on precision ophthalmology, improved patient access to specialized care, and the integration of personalized medicine approaches, fueling transformative growth within the broader retinitis pigmentosa treatment and management industry.

The autosomal recessive retinitis pigmentosa market is projected to grow by \$2,810 million, the retinitis pigmentosa specialty clinics market by \$2,515 million, the online pharmacy for retinitis pigmentosa market by \$2,275 million, the electroretinogram retinitis pigmentosa market by \$2,229 million, and the retinitis pigmentosa and vitamin A therapeutics market by \$1,618 million over the next five years from 2024 to 2029.

## Learn More About The Business Research Company

The Business Research Company ([www.thebusinessresearchcompany.com](http://www.thebusinessresearchcompany.com)) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

### Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: [info@tbrc.info](mailto:info@tbrc.info)

### Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham

The Business Research Company

+44 7882 955267

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/876478209>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.